Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2019 | Ionizing Radiation | Research

Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase

Authors: Ignacio Campillo-Marcos, Pedro A. Lazo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Abstract

Background

The VRK1 chromatin kinase regulates the organization of locally altered chromatin induced by DNA damage. The combination of ionizing radiation with inhibitors of DNA damage responses increases the accumulation of DNA damage in cancer cells, which facilitates their antitumor effect, a process regulated by VRK1.

Methods

Tumor cell lines with different genetic backgrounds were treated with olaparib to determine their effect on the activation of DNA repair pathways induced by ionizing radiation. The effect of combining olaparib with depletion of the chromatin kinase VRK1 was studied in the context of double-strand breaks repair pathway after treatment with ionizing radiation. The initiation and progression of DDR were studied by specific histone acetylation, as a marker of local chromatin relaxation, and formation of γH2AX and 53BP1 foci.

Results

In this work, we have studied the effect that VRK1 by itself or in collaboration with olaparib, an inhibitor of PARP, has on the DNA oxidative damage induced by irradiation in order to identify its potential as a new drug target. The combination of olaparib and ionizing radiation increases DNA damage permitting a significant reduction of their respective doses to achieve a similar amount of DNA damage detected by γH2AX and 53BP1 foci. Different treatment combinations of olaparib and ionizing radiation permitted to reach the maximum level of DNA damage at lower doses of both treatments. Furthermore, we have studied the effect that depletion of the VRK1 chromatin kinase, a regulator of DDR, has on this response. VRK1 knockdown impaired all steps in the DDR induced by these treatments, which were detected by a reduction of sequential markers such as H4K16 ac, γH2AX, NBS1 and 53BP1. Moreover, this effect of VRK1 is independent of TP53 or ATM, two genes frequently mutated in cancer.

Conclusion

The protective DNA damage response induced by ionizing radiation is impaired by the combination of olaparib with depletion of VRK1, and can be used to reduce doses of radiation and their associated toxicity. Proteins implicated in DNA damage responses are suitable targets for development of new therapeutic strategies and their combination can be an alternative form of synthetic lethality.

Available only for authorised users

O'Connor MJ. Targeting the DNA damage response in Cancer. Mol Cell. 2015;60:547–60. https://doi.org/10.1016/j.molcel.2015.10.040.CrossRefPubMed

Alkan O, Schoeberl B, Shah M, Koshkaryev A, Heinemann T, Drummond DC, Yaffe MB, Raue A. Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway. Sci Signal. 2018;11. https://doi.org/10.1126/scisignal.aat0229.

Ball AR Jr, Yokomori K. Damage site chromatin: open or closed? Curr Opin Cell Biol. 2011;23:277–83. https://doi.org/10.1016/j.ceb.2011.03.012.CrossRefPubMedPubMedCentral

Bakkenist CJ, Kastan MB. Chromatin perturbations during the DNA damage response in higher eukaryotes. DNA Repair (Amst). 2015;36:8–12. https://doi.org/10.1016/j.dnarep.2015.09.002.CrossRef

Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in Cancer: beyond PARP inhibitors. Cancer Discov. 2017;7:20–37. https://doi.org/10.1158/2159-8290.CD-16-0860.CrossRefPubMed

Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610–21. https://doi.org/10.1038/nrm.2017.53.CrossRefPubMed

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP inhibitors in prostate Cancer. Curr Treat Options in Oncol. 2017;18:37. https://doi.org/10.1007/s11864-017-0480-2.CrossRef

Kotter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour WY. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells. Mol Oncol. 2014;8:1616–25. https://doi.org/10.1016/j.molonc.2014.06.008.CrossRefPubMedPubMedCentral

Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10:1949–58. https://doi.org/10.1158/1535-7163.MCT-11-0278.CrossRefPubMedPubMedCentral

10.

Gravells P, Neale J, Grant E, Nathubhai A, Smith KM, James DI, Bryant HE. Radiosensitization with an inhibitor of poly (ADP-ribose) glycohydrolase: a comparison with the PARP1/2/3 inhibitor olaparib. DNA Repair (Amst). 2018;61:25–36. https://doi.org/10.1016/j.dnarep.2017.11.004.CrossRef

11.

Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, et al. Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma. Mol Cancer Ther. 2015;14:2560–8. https://doi.org/10.1158/1535-7163.MCT-15-0282.CrossRefPubMed

12.

Rae C, Mairs RJ. Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells. Int J Radiat Biol. 2017;93:194–203. https://doi.org/10.1080/09553002.2017.1231946.CrossRefPubMed

13.

McMahon M, Frangova TG, Henderson CJ, Wolf CR. Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in Normal tissues: insights from a new p21 reporter mouse. Mol Cancer Res. 2016;14:1195–203. https://doi.org/10.1158/1541-7786.MCR-16-0108.CrossRefPubMedPubMedCentral

14.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, et al. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018;37:2793–805. https://doi.org/10.1038/s41388-018-0130-6.CrossRefPubMedPubMedCentral

15.

Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP. ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010;9:347–57. https://doi.org/10.1158/1535-7163.MCT-09-0872.CrossRefPubMedPubMedCentral

16.

Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, Bebb DG. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014;13:2129–37. https://doi.org/10.4161/cc.29212.CrossRefPubMedPubMedCentral

17.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34. https://doi.org/10.1056/NEJMoa0900212.CrossRefPubMed

18.

Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512–9. https://doi.org/10.1200/JCO.2009.26.9589.CrossRef

19.

Campillo-Marcos I, Lazo PA. Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target? Cell Mol Life Sci. 2018;75:2375–88. https://doi.org/10.1007/s00018-018-2811-2.CrossRefPubMedPubMedCentral

20.

Sanz-Garcia M, Monsalve DM, Sevilla A, Lazo PA. Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage. J Biol Chem. 2012;287:23757–68. https://doi.org/10.1074/jbc.M112.353102.CrossRefPubMedPubMedCentral

21.

Cantarero L, Moura DS, Salzano M, Monsalve DM, Campillo-Marcos I, Martín-Doncel E, Lazo PA: VRK1 (vaccinia-related kinase 1). In Encyclopedia of Signaling Molecules, 2nd Ed (Choi S ed.: springer Science; 2017. doi: https://doi.org/10.1007/978-1-4614-6438-9_561-2.

22.

Valbuena A, Sanz-Garcia M, Lopez-Sanchez I, Vega FM, Lazo PA. Roles of VRK1 as a new player in the control of biological processes required for cell division. Cell Signal. 2011;23:1267–72. https://doi.org/10.1016/j.cellsig.2011.04.002.CrossRefPubMed

23.

Monsalve DM, Campillo-Marcos I, Salzano M, Sanz-Garcia M, Cantarero L, Lazo PA. VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage. BBA Mol Cell Res. 2016;1863:760–9. https://doi.org/10.1016/j.bbamcr.2016.02.005.CrossRef

24.

Salzano M, Sanz-Garcia M, Monsalve DM, Moura DS, Lazo PA. VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage. Epigenetics. 2015;10:373–83. https://doi.org/10.1080/15592294.2015.1028708.CrossRefPubMedPubMedCentral

25.

Moura DS, Campillo-Marcos I, Vazquez-Cedeira M, Lazo PA. VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis. Cell Mol Life Sci. 2018;76:2591–611. https://doi.org/10.1007/s00018-018-2746-7.CrossRef

26.

Salzano M, Vazquez-Cedeira M, Sanz-Garcia M, Valbuena A, Blanco S, Fernandez IF, Lazo PA. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. Oncotarget. 2014;5:1770–8. https://doi.org/10.18632/oncotarget.1678.CrossRefPubMedPubMedCentral

27.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One. 2008;3:e2994. https://doi.org/10.1371/journal.pone.0002994.CrossRefPubMedPubMedCentral

28.

Ben Z, Gong L, Qiu Y. High expression of VRK1 is related to poor prognosis in glioma. Pathol Res Pract. 2018;214:112–8. https://doi.org/10.1016/j.prp.2017.10.014.CrossRefPubMed

29.

Kilpinen S, Ojala K, Kallioniemi O. Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome. PLoS One. 2010;5:e15068. https://doi.org/10.1371/journal.pone.0015068.CrossRefPubMedPubMedCentral

30.

Huang W, Cui X, Chen Y, Shao M, Shao X, Shen Y, Liu Q, Wu M, Liu J, Ni W, et al. High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma. Pathol Res Pract. 2016;212:171–8. https://doi.org/10.1016/j.prp.2015.11.015.CrossRefPubMed

31.

Cantarero L, Sanz-Garcia M, Vinograd-Byk H, Renbaum P, Levy-Lahad E, Lazo PA. VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle. Sci Rep. 2015;5:10543. https://doi.org/10.1038/srep10543.CrossRefPubMedPubMedCentral

32.

Moura DS, Fernandez IF, Marin-Royo G, Lopez-Sanchez I, Martin-Doncel E, Vega FM, Lazo PA. Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation. Sci Rep. 2016;6:28532. https://doi.org/10.1038/srep28532.CrossRefPubMedPubMedCentral

33.

Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc. 2007;2:1445–57. https://doi.org/10.1038/nprot.2007.202.CrossRefPubMed

34.

Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology. 2004;328:254–65. https://doi.org/10.1016/j.virol.2004.08.013.CrossRefPubMed

35.

Bremer M, Doerge RM: Statistics at the bench: a step-by step handbook for biologists. New York: Cold Spring Harbor Laboratory Press; 2009. ISBN: 978-0-97969-857-7.

36.

Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957–67. https://doi.org/10.1038/nrc2523.CrossRefPubMedPubMedCentral

37.

Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15:7–18. https://doi.org/10.1038/nrm3719.CrossRefPubMed

38.

Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, Typas D, Lammers M, Mailand N, Nussenzweig A, et al. DNA repair network analysis reveals Shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity. Cell. 2018;173:972–988 e923. https://doi.org/10.1016/j.cell.2018.03.050.CrossRefPubMed

39.

Lazo PA. Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression. Cell Signal. 2017;33:49–58. https://doi.org/10.1016/j.cellsig.2017.02.005.CrossRefPubMed

40.

Xu Y, Price BD. Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle. 2011;10:261–7. https://doi.org/10.4161/cc.10.2.14543.

41.

Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006;311:844–7. https://doi.org/10.1126/science.1124000.CrossRefPubMed

42.

Sanchez-Molina S, Estaras C, Oliva JL, Akizu N, Asensio-Juan E, Rojas JM, Martinez-Balbas MA. Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation. Carcinogenesis. 2014;35:2194–202. https://doi.org/10.1093/carcin/bgu111.CrossRefPubMed

43.

Renaud E, Barascu A, Rosselli F. Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells. Nucleic Acids Res. 2016;44:648–56. https://doi.org/10.1093/nar/gkv1019.CrossRefPubMed

44.

Krishnan V, Chow MZ, Wang Z, Zhang L, Liu B, Liu X, Zhou Z. Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc Natl Acad Sci U S A. 2011;108:12325–30. https://doi.org/10.1073/pnas.1102789108.CrossRefPubMedPubMedCentral

45.

Valbuena A, Lopez-Sanchez I, Lazo PA. Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS One. 2008;3:e1642. https://doi.org/10.1371/journal.pone.0001642.CrossRefPubMedPubMedCentral

46.

Kang TH, Park DY, Kim W, Kim KT. VRK1 phosphorylates CREB and mediates CCND1 expression. J Cell Sci. 2008;121:3035–41. https://doi.org/10.1242/jcs.026757.CrossRefPubMed

47.

Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, et al. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013;4:1701. https://doi.org/10.1038/ncomms2660.CrossRefPubMedPubMedCentral

48.

Kang TH, Park DY, Choi YH, Kim KJ, Yoon HS, Kim KT. Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol Cell Biol. 2007;27:8533–46. https://doi.org/10.1128/MCB.00018-07.CrossRefPubMedPubMedCentral

49.

Molitor TP, Traktman P. Depletion of the protein kinase VRK1 disrupts nuclear envelope morphology and leads to BAF retention on mitotic chromosomes. Mol Biol Cell. 2014;25:891–903. https://doi.org/10.1091/mbc.E13-10-0603.CrossRefPubMedPubMedCentral

50.

Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst). 2010;9:1299–306. https://doi.org/10.1016/j.dnarep.2010.10.001.CrossRef

51.

Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol. 2011;12:90–103. https://doi.org/10.1038/nrm3047.CrossRefPubMedPubMedCentral

52.

Vega FM, Sevilla A, Lazo PA. p53 stabilization and accumulation induced by human vaccinia-related kinase 1. Mol Cell Biol. 2004;24:10366–80. https://doi.org/10.1128/MCB.24.23.10366-10380.2004.CrossRefPubMedPubMedCentral

53.

Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VRK1 by p53 in response to DNA damage is mediated by the Autophagic pathway. PLoS One. 2011;6:e17320. https://doi.org/10.1371/journal.pone.0017320.CrossRefPubMedPubMedCentral

54.

Lopez-Sanchez I, Valbuena A, Vazquez-Cedeira M, Khadake J, Sanz-Garcia M, Carrillo-Jimenez A, Lazo PA. VRK1 interacts with p53 forming a basal complex that is activated by UV-induced DNA damage. FEBS Lett. 2014;588:692–700. https://doi.org/10.1016/j.febslet.2014.01.040.CrossRefPubMed

55.

Lopez-Borges S, Lazo PA. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene. 2000;19:3656–64. https://doi.org/10.1038/sj.onc.1203709.CrossRefPubMed

56.

Valbuena A, Suarez-Gauthier A, Lopez-Rios F, Lopez-Encuentra A, Blanco S, Fernandez PL, Sanchez-Cespedes M, Lazo PA. Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer. 2007;58:303–9. https://doi.org/10.1016/j.lungcan.2007.06.023.CrossRefPubMed

57.

Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, et al. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer. 2017;84:290–303. https://doi.org/10.1016/j.ejca.2017.07.026.CrossRefPubMed

58.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17:209–22. https://doi.org/10.1038/nrc.2016.154.CrossRefPubMedPubMedCentral

59.

Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, Schwaller J, Sundstrom M, Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007;104:20523–8. https://doi.org/10.1073/pnas.0708800104.CrossRefPubMedPubMedCentral

60.

Fedorov O, Sundstrom M, Marsden B, Knapp S. Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov Today. 2007;12:365–72. https://doi.org/10.1016/j.drudis.2007.03.006.CrossRefPubMed

61.

Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 2008;68:767–76. https://doi.org/10.1158/0008-5472.CAN-07-5516.CrossRefPubMed

62.

Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 2006;66:7095–102. https://doi.org/10.1158/0008-5472.CAN-06-0515.CrossRefPubMedPubMedCentral

63.

Hennig EE, Mikula M, Rubel T, Dadlez M, Ostrowski J. Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med. 2012;90:447–56. https://doi.org/10.1007/s00109-011-0831-6.CrossRefPubMed

64.

Kiessling MK, Schuierer S, Stertz S, Beibel M, Bergling S, Knehr J, Carbone W, de Valliere C, Tchinda J, Bouwmeester T, et al. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. BMC Genomics. 2016;17:723. https://doi.org/10.1186/s12864-016-3042-2.CrossRefPubMedPubMedCentral

65.

Molitor TP, Traktman P. Molecular genetic analysis of VRK1 in mammary epithelial cells: depletion slows proliferation in vitro and tumor growth and metastasis in vivo. Oncogenesis. 2013;2:e48. https://doi.org/10.1038/oncsis.2013.11.CrossRefPubMedPubMedCentral

66.

Mon AM, MacKinnon AC Jr, Traktman P. Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells. PLoS One. 2018;13:e0203397. https://doi.org/10.1371/journal.pone.0203397.CrossRefPubMedPubMedCentral

67.

Valbuena A, Vega FM, Blanco S, Lazo PA. p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol. 2006;26:4782–93. https://doi.org/10.1128/MCB.00069-06.CrossRefPubMedPubMedCentral

68.

Valbuena A, Blanco S, Vega FM, Lazo PA. The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53. PLoS One. 2008;3:e2649. https://doi.org/10.1371/journal.pone.0002649.CrossRefPubMedPubMedCentral

69.

Vazquez-Cedeira M, Barcia-Sanjurjo I, Sanz-Garcia M, Barcia R, Lazo PA. Differential inhibitor sensitivity between human kinases VRK1 and VRK2. PLoS One. 2011;6:e23235. https://doi.org/10.1371/journal.pone.0023235.CrossRefPubMedPubMedCentral

70.

Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017;552:116–20. https://doi.org/10.1038/nature24673.CrossRefPubMed

71.

Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget. 2018;9:7949–60. https://doi.org/10.18632/oncotarget.23742.CrossRefPubMed

72.

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9. https://doi.org/10.1126/scitranslmed.aal4922.

73.

Yin M, Grivas P, Emamekhoo H, Mendiratta P, Ali S, Hsu J, Vasekar M, Drabick JJ, Pal S, Joshi M. ATM/RB1 mutations predict shorter overall survival in urothelial cancer. Oncotarget. 2018;9:16891–8. https://doi.org/10.18632/oncotarget.24738.CrossRefPubMedPubMedCentral

74.

Valbuena A, Lopez-Sanchez I, Vega FM, Sevilla A, Sanz-Garcia M, Blanco S, Lazo PA. Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations. Arch Biochem Biophys. 2007;465:219–26. https://doi.org/10.1016/j.abb.2007.06.005.CrossRefPubMed

Title: Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase
Authors: Ignacio Campillo-Marcos
Pedro A. Lazo
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Ionizing Radiation
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-019-1204-1

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity

Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils

LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus

Correction to: Molecular pattern of lncRNAs in hepatocellular carcinoma

Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma